Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Spinal α2δ-1 induces GluA3 degradation to regulate assembly of calcium-permeable AMPA receptors and pain hypersensitivity
Meng-Hua Zhou, Shao-Rui Chen, Daozhong Jin, Yuying Huang, Hong Chen, Guanxing Chen, Jiusheng Yan, Hui-Lin Pan
Meng-Hua Zhou, Shao-Rui Chen, Daozhong Jin, Yuying Huang, Hong Chen, Guanxing Chen, Jiusheng Yan, Hui-Lin Pan
View: Text | PDF
Research Article Aging Neuroscience

Spinal α2δ-1 induces GluA3 degradation to regulate assembly of calcium-permeable AMPA receptors and pain hypersensitivity

  • Text
  • PDF
Abstract

The increased prevalence of GluA2-lacking, Ca2+-permeable AMPA receptors (CP-AMPARs) at spinal cord sensory synapses amplifies nociceptive transmission and maintains chronic neuropathic pain. Nerve injury–induced upregulation of α2δ-1 disrupts the assembly of GluA1/GluA2 heteromers, favoring the synaptic incorporation of GluA1 homotetramers in the spinal dorsal horn. Although GluA1-GluA3 subunits are broadly expressed, whether α2δ-1 regulates GluA3-containing AMPARs remains unknown. Here, we unexpectedly found that coexpression with α2δ-1 — but not α2δ-2 or α2δ-3 — diminished GluA3 AMPAR currents and protein levels, an effect blocked by pregabalin, an α2δ-1 C-terminus peptide, or proteasome inhibition. Both nerve injury and α2δ-1 overexpression reduced protein levels of GluA3 and GluA2/GluA3 heteromers in the spinal cord. Furthermore, α2δ-1 coexpression or nerve injury increased GluA3 ubiquitination, with K861 at the C-terminus of GluA3 identified as a key ubiquitination site mediating α2δ-1–induced GluA3 degradation. Additionally, intrathecal delivery of the Gria3 gene reversed nerve injury–induced nociceptive hypersensitivity and synaptic CP-AMPARs by restoring protein levels of GluA3 and GluA2/GluA3 heteromers in the spinal cord. These findings reveal that α2δ-1 promotes GluA1 homotetramer assembly and synaptic CP-AMPAR expression by driving ubiquitin-proteasome–mediated degradation of GluA3, providing insights into the molecular mechanisms of neuropathic pain and the therapeutic actions of gabapentinoids.

Authors

Meng-Hua Zhou, Shao-Rui Chen, Daozhong Jin, Yuying Huang, Hong Chen, Guanxing Chen, Jiusheng Yan, Hui-Lin Pan

×

Figure 10

Intrathecal Gria3 delivery reverses nerve injury–induced pain hypersensitivity and synaptic CP-AMPARs by promoting GluA2/GluA3 formation in the spinal cord.

Options: View larger image (or click on image) Download as PowerPoint
Intrathecal Gria3 delivery reverses nerve injury–induced pain hypersensi...
(A) Changes in the hindpaw withdrawal thresholds of sham control and SNL rats 2 and 3 weeks after intrathecal injection of control (Cont) lentiviral vectors or lentiviral vectors expressing Gria3 (n = 13 rats per group). **P < 0.01, ***P < 0.001; 2-way ANOVA followed by Tukey’s post hoc test. (B and C) Representative immunoblot images (B) and quantification (C) show the protein levels of GluA3 and GluA2/GluA3 complexes in the dorsal spinal cords of sham control and SNL rats treated with intrathecal control lentiviruses or Gria3-expressing lentiviruses (n = 8 rats per group). Protein extracts from spinal cord tissues were immunoprecipitated (IP) using a GluA2 antibody or IgG. Immunoblotting was then conducted using GluA2, GluA3, and β-actin antibodies. β-Actin protein bands were used as the internal control on the same gel. **P < 0.01, ***P < 0.001; 2-way ANOVA followed by Tukey’s post hoc test. (D and E) Representative recording traces (D) and quantification (E) show the differential effect of bath application of IEM-1460 (50 μM) on the amplitude of monosynaptic AMPAR-EPSCs in spinal lamina II neurons from SNL rats treated with intrathecal injection of control lentiviruses or Gria3-expressing lentiviruses (n = 18 neurons from 4 rats per group). Data were normalized to the baseline value (100%) before IEM-1460 application. *P < 0.05, **P < 0.01 versus control vector group at the same time point; 2-way ANOVA followed by Tukey’s post hoc test. Data are presented as mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts